“…Between 2016 and 2020, 14 EU countries (Austria, Belgium, Denmark, Estonia, France, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Slovenia, Spain and Sweden) reported antimicrobial susceptibility results for monophasic S. Typhimurium 1,4, [5],12:i:-on the antimicrobial classes mentioned above to TESSy. Of 7 157 tested isolates, only 37 (0.5%) were resistant to ampicillin, sulfonamides, tetracycline, gentamicin (streptomycin and kanamycin data not collected), chloramphenicol and trimethoprim while being susceptible to ciprofloxacin and cefotaxime/ceftazidime, with the highest number of cases in 2018 (Figure A2).…”